



Reference: ITAP - Circulars
Contact person: Danie Kolver
Tel: 012-4310509/10
Fax: 086 682 9646
E-mail: d.kolver@medicalschemes.com
Date: 13 October 2017

Circular 64 of 2017: Measuring the quality, outcomes and value proposition of managed care interventions in respect of Epilepsy and Parkinson Disease

The Managed Task Team 1, one of the task teams of the Industry Technical Advisory Panel (ITAP), has recently completed a project that focused on developing measures for the measurement of the quality, outcomes, and ultimately the value proposition of managed care interventions. The initiative is focused on the impact of managed care insofar as the techniques relating to funding of benefits for medical scheme beneficiaries are concerned.

Managed care organisations are required to demonstrate their value proposition as it relates to the manner in which they render managed care services to beneficiaries of medical schemes. The introduction of entry level criteria, process indicators and clinical outcomes measures for chronic disease conditions will enable the Council for Medical Schemes (CMS) to assess, guide, monitor and promote the measuring of value of managed care interventions offered to beneficiaries. Medical schemes will similarly be required to report forthwith on these process indicators and outcomes achieved in the annual statutory returns (ASR).

The task team has completed the minimum data specifications with regard to the conditions referred to herein, which are published as a final version for implementation. The CMS values the contributions made by the relevant role players who participated in the process, and is looking forward to continue with the work on the remaining conditions in the near future.

Information on the progress with managed care interventions on Glaucoma and Haemophilia will be published in due course. This circular covers the condition listed below.

- [Epilepsy and Parkinson Disease](#)



Dr S Kabane
Acting Chief Executive and Registrar
Council for Medical Schemes